Vytrus Biotech will destinate an important sum of money in R&D for dermocosmetics and health projects. The Catalan company referent in active ingredients derived of the cells vegetal mother has received €575.000 by part of The Centre for Technological Development and the Innovation (CDTI).
Vytrus will allocate this future quantity projects of development dermocosmético and to new technological platforms for the production of active ingredients hybrids with high potential for the health and the human welfare. As it has indicated the own company in a press release, 137 one thousand euros correspond to a no refundable stretch and the rest is a loan on a long-term basis for the company.
In words of the CEO and cofounder of Vytrus Biotech, Albert Jané of Vytrus Biotech has explained that thanks to this project, the company will be able to keep the high level of innovation and this will allow to diversify with new technologies the portafolio of products of high efficiency, sustainable and innovative.
The finance conceded by the CDTI for the project has had the cofinanciación of the Bottoms Next Generation, vehiculizados through the FEDER (European Bottom of Regional Development of the European Union).